ARCHIVES

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

TTF Increased Survival Compared To Chemotherapy

December 31, 2010

New Therapies For Genitourinary Cancers In Clinical Testing Presented At ASCO

July 25, 2003

Seattle Panel Meeting Generate More Support For Increased Outreach Funding, Consortium Approached

November 2, 1984

NCI Study Finds No Greater Cancer Risk Near Nuclear Plants

September 28, 1990

Bristol-Myers Runs Afoul Of FDA In Attempt To Distribute Chapters of Oncology Textbook

June 19, 1992

Firm Begins Phase II Trial Of LDP-341 For Myeloma.

March 30, 2001